---
document_datetime: 2025-12-02 05:38:25
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/zynquista.html
document_name: zynquista.html
version: success
processing_time: 0.1037691
conversion_datetime: 2025-12-27 23:07:44.825217
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Zynquista

[RSS](/en/individual-human-medicine.xml/67201)

##### Withdrawn

This medicine's authorisation has been withdrawn

sotagliflozin Medicine Human Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Zynquista](#news-on)
- [More information on Zynquista](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 22 March 2022, the European Commission withdrew the marketing authorisation for Zynquista (sotagliflozin) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Guidehouse Germany GmbH, which notified the European Commission of its decision not to market the product in the EU for commercial reasons.

Zynquista was granted marketing authorisation in the EU on 26 April 2019 for use as an adjunct to insulin therapy to improve glycaemic control in adults with type 1 diabetes mellitus. The marketing authorisation was initially valid for a 5-year period.

The European Public Assessment Report (EPAR) for Zynquista is updated to indicate that the marketing authorisation is no longer valid.

Zynquista : EPAR - Medicine overview

English (EN) (665.64 KB - PDF)

**First published:** 16/05/2019

**Last updated:** 16/08/2022

[View](/en/documents/overview/zynquista-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-601)

български (BG) (759.4 KB - PDF)

**First published:**

16/05/2019

**Last updated:**

16/08/2022

[View](/bg/documents/overview/zynquista-epar-medicine-overview_bg.pdf)

español (ES) (663.54 KB - PDF)

**First published:**

16/05/2019

**Last updated:**

16/08/2022

[View](/es/documents/overview/zynquista-epar-medicine-overview_es.pdf)

čeština (CS) (739.92 KB - PDF)

**First published:**

16/05/2019

**Last updated:**

16/08/2022

[View](/cs/documents/overview/zynquista-epar-medicine-overview_cs.pdf)

dansk (DA) (661.62 KB - PDF)

**First published:**

16/05/2019

**Last updated:**

16/08/2022

[View](/da/documents/overview/zynquista-epar-medicine-overview_da.pdf)

Deutsch (DE) (665.21 KB - PDF)

**First published:**

16/05/2019

**Last updated:**

16/08/2022

[View](/de/documents/overview/zynquista-epar-medicine-overview_de.pdf)

eesti keel (ET) (660.61 KB - PDF)

**First published:**

16/05/2019

**Last updated:**

16/08/2022

[View](/et/documents/overview/zynquista-epar-medicine-overview_et.pdf)

ελληνικά (EL) (768.79 KB - PDF)

**First published:**

16/05/2019

**Last updated:**

16/08/2022

[View](/el/documents/overview/zynquista-epar-medicine-overview_el.pdf)

français (FR) (664.42 KB - PDF)

**First published:**

16/05/2019

**Last updated:**

16/08/2022

[View](/fr/documents/overview/zynquista-epar-medicine-overview_fr.pdf)

hrvatski (HR) (687.88 KB - PDF)

**First published:**

16/05/2019

**Last updated:**

16/08/2022

[View](/hr/documents/overview/zynquista-epar-medicine-overview_hr.pdf)

italiano (IT) (662 KB - PDF)

**First published:**

16/05/2019

**Last updated:**

16/08/2022

[View](/it/documents/overview/zynquista-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (745.89 KB - PDF)

**First published:**

16/05/2019

**Last updated:**

16/08/2022

[View](/lv/documents/overview/zynquista-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (690.02 KB - PDF)

**First published:**

16/05/2019

**Last updated:**

16/08/2022

[View](/lt/documents/overview/zynquista-epar-medicine-overview_lt.pdf)

magyar (HU) (732.62 KB - PDF)

**First published:**

16/05/2019

**Last updated:**

16/08/2022

[View](/hu/documents/overview/zynquista-epar-medicine-overview_hu.pdf)

Malti (MT) (747.05 KB - PDF)

**First published:**

16/05/2019

**Last updated:**

16/08/2022

[View](/mt/documents/overview/zynquista-epar-medicine-overview_mt.pdf)

Nederlands (NL) (662.97 KB - PDF)

**First published:**

16/05/2019

**Last updated:**

16/08/2022

[View](/nl/documents/overview/zynquista-epar-medicine-overview_nl.pdf)

polski (PL) (737.08 KB - PDF)

**First published:**

16/05/2019

**Last updated:**

16/08/2022

[View](/pl/documents/overview/zynquista-epar-medicine-overview_pl.pdf)

português (PT) (663.6 KB - PDF)

**First published:**

16/05/2019

**Last updated:**

16/08/2022

[View](/pt/documents/overview/zynquista-epar-medicine-overview_pt.pdf)

română (RO) (688.26 KB - PDF)

**First published:**

16/05/2019

**Last updated:**

16/08/2022

[View](/ro/documents/overview/zynquista-epar-medicine-overview_ro.pdf)

slovenčina (SK) (737.1 KB - PDF)

**First published:**

16/05/2019

**Last updated:**

16/08/2022

[View](/sk/documents/overview/zynquista-epar-medicine-overview_sk.pdf)

slovenščina (SL) (730.05 KB - PDF)

**First published:**

16/05/2019

**Last updated:**

16/08/2022

[View](/sl/documents/overview/zynquista-epar-medicine-overview_sl.pdf)

Suomi (FI) (661.18 KB - PDF)

**First published:**

16/05/2019

**Last updated:**

16/08/2022

[View](/fi/documents/overview/zynquista-epar-medicine-overview_fi.pdf)

svenska (SV) (662.66 KB - PDF)

**First published:**

16/05/2019

**Last updated:**

16/08/2022

[View](/sv/documents/overview/zynquista-epar-medicine-overview_sv.pdf)

Zynquista : EPAR - Risk-management-plan summary

English (EN) (720.08 KB - PDF)

**First published:** 16/05/2019

**Last updated:** 16/08/2022

[View](/en/documents/rmp-summary/zynquista-epar-risk-management-plan-summary_en.pdf)

## Product information

Zynquista : EPAR - Product information

English (EN) (1.18 MB - PDF)

**First published:** 16/05/2019

**Last updated:** 16/08/2022

[View](/en/documents/product-information/zynquista-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-870)

български (BG) (2.39 MB - PDF)

**First published:**

16/05/2019

**Last updated:**

16/08/2022

[View](/bg/documents/product-information/zynquista-epar-product-information_bg.pdf)

español (ES) (1.23 MB - PDF)

**First published:**

16/05/2019

**Last updated:**

16/08/2022

[View](/es/documents/product-information/zynquista-epar-product-information_es.pdf)

čeština (CS) (2.05 MB - PDF)

**First published:**

16/05/2019

**Last updated:**

16/08/2022

[View](/cs/documents/product-information/zynquista-epar-product-information_cs.pdf)

dansk (DA) (1.2 MB - PDF)

**First published:**

16/05/2019

**Last updated:**

16/08/2022

[View](/da/documents/product-information/zynquista-epar-product-information_da.pdf)

Deutsch (DE) (1.25 MB - PDF)

**First published:**

16/05/2019

**Last updated:**

16/08/2022

[View](/de/documents/product-information/zynquista-epar-product-information_de.pdf)

eesti keel (ET) (1.23 MB - PDF)

**First published:**

16/05/2019

**Last updated:**

16/08/2022

[View](/et/documents/product-information/zynquista-epar-product-information_et.pdf)

ελληνικά (EL) (2.54 MB - PDF)

**First published:**

16/05/2019

**Last updated:**

16/08/2022

[View](/el/documents/product-information/zynquista-epar-product-information_el.pdf)

français (FR) (1.33 MB - PDF)

**First published:**

16/05/2019

**Last updated:**

16/08/2022

[View](/fr/documents/product-information/zynquista-epar-product-information_fr.pdf)

hrvatski (HR) (1.3 MB - PDF)

**First published:**

16/05/2019

**Last updated:**

16/08/2022

[View](/hr/documents/product-information/zynquista-epar-product-information_hr.pdf)

íslenska (IS) (1.19 MB - PDF)

**First published:**

16/05/2019

**Last updated:**

16/08/2022

[View](/is/documents/product-information/zynquista-epar-product-information_is.pdf)

italiano (IT) (1.3 MB - PDF)

**First published:**

16/05/2019

**Last updated:**

16/08/2022

[View](/it/documents/product-information/zynquista-epar-product-information_it.pdf)

latviešu valoda (LV) (2.11 MB - PDF)

**First published:**

16/05/2019

**Last updated:**

16/08/2022

[View](/lv/documents/product-information/zynquista-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.36 MB - PDF)

**First published:**

16/05/2019

**Last updated:**

16/08/2022

[View](/lt/documents/product-information/zynquista-epar-product-information_lt.pdf)

magyar (HU) (2.03 MB - PDF)

**First published:**

16/05/2019

**Last updated:**

16/08/2022

[View](/hu/documents/product-information/zynquista-epar-product-information_hu.pdf)

Malti (MT) (2.12 MB - PDF)

**First published:**

16/05/2019

**Last updated:**

16/08/2022

[View](/mt/documents/product-information/zynquista-epar-product-information_mt.pdf)

Nederlands (NL) (1.29 MB - PDF)

**First published:**

16/05/2019

**Last updated:**

16/08/2022

[View](/nl/documents/product-information/zynquista-epar-product-information_nl.pdf)

norsk (NO) (1.17 MB - PDF)

**First published:**

16/05/2019

**Last updated:**

16/08/2022

[View](/no/documents/product-information/zynquista-epar-product-information_no.pdf)

polski (PL) (2.08 MB - PDF)

**First published:**

16/05/2019

**Last updated:**

16/08/2022

[View](/pl/documents/product-information/zynquista-epar-product-information_pl.pdf)

português (PT) (1.21 MB - PDF)

**First published:**

16/05/2019

**Last updated:**

16/08/2022

[View](/pt/documents/product-information/zynquista-epar-product-information_pt.pdf)

română (RO) (1.43 MB - PDF)

**First published:**

16/05/2019

**Last updated:**

16/08/2022

[View](/ro/documents/product-information/zynquista-epar-product-information_ro.pdf)

slovenčina (SK) (2.03 MB - PDF)

**First published:**

16/05/2019

**Last updated:**

16/08/2022

[View](/sk/documents/product-information/zynquista-epar-product-information_sk.pdf)

slovenščina (SL) (1.95 MB - PDF)

**First published:**

16/05/2019

**Last updated:**

16/08/2022

[View](/sl/documents/product-information/zynquista-epar-product-information_sl.pdf)

Suomi (FI) (1.19 MB - PDF)

**First published:**

16/05/2019

**Last updated:**

16/08/2022

[View](/fi/documents/product-information/zynquista-epar-product-information_fi.pdf)

svenska (SV) (1.21 MB - PDF)

**First published:**

16/05/2019

**Last updated:**

16/08/2022

[View](/sv/documents/product-information/zynquista-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** IAIN/0005 22/03/2022

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Zynquista : EPAR - All Authorised presentations

English (EN) (593.92 KB - PDF)

**First published:** 16/05/2019

**Last updated:** 16/08/2022

[View](/en/documents/all-authorised-presentations/zynquista-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-328)

български (BG) (671.74 KB - PDF)

**First published:**

16/05/2019

**Last updated:**

16/08/2022

[View](/bg/documents/all-authorised-presentations/zynquista-epar-all-authorised-presentations_bg.pdf)

español (ES) (586.22 KB - PDF)

**First published:**

16/05/2019

**Last updated:**

16/08/2022

[View](/es/documents/all-authorised-presentations/zynquista-epar-all-authorised-presentations_es.pdf)

čeština (CS) (687.23 KB - PDF)

**First published:**

16/05/2019

**Last updated:**

16/08/2022

[View](/cs/documents/all-authorised-presentations/zynquista-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (626.01 KB - PDF)

**First published:**

16/05/2019

**Last updated:**

16/08/2022

[View](/da/documents/all-authorised-presentations/zynquista-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (601.85 KB - PDF)

**First published:**

16/05/2019

**Last updated:**

16/08/2022

[View](/de/documents/all-authorised-presentations/zynquista-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (636.13 KB - PDF)

**First published:**

16/05/2019

**Last updated:**

16/08/2022

[View](/et/documents/all-authorised-presentations/zynquista-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (631.56 KB - PDF)

**First published:**

16/05/2019

**Last updated:**

16/08/2022

[View](/el/documents/all-authorised-presentations/zynquista-epar-all-authorised-presentations_el.pdf)

français (FR) (594.11 KB - PDF)

**First published:**

16/05/2019

**Last updated:**

16/08/2022

[View](/fr/documents/all-authorised-presentations/zynquista-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (636.11 KB - PDF)

**First published:**

16/05/2019

**Last updated:**

16/08/2022

[View](/hr/documents/all-authorised-presentations/zynquista-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (672.09 KB - PDF)

**First published:**

16/05/2019

**Last updated:**

16/08/2022

[View](/is/documents/all-authorised-presentations/zynquista-epar-all-authorised-presentations_is.pdf)

italiano (IT) (583.43 KB - PDF)

**First published:**

16/05/2019

**Last updated:**

16/08/2022

[View](/it/documents/all-authorised-presentations/zynquista-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (658.25 KB - PDF)

**First published:**

16/05/2019

**Last updated:**

16/08/2022

[View](/lv/documents/all-authorised-presentations/zynquista-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (88.55 KB - PDF)

**First published:**

16/05/2019

**Last updated:**

16/08/2022

[View](/lt/documents/all-authorised-presentations/zynquista-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (651.75 KB - PDF)

**First published:**

16/05/2019

**Last updated:**

16/08/2022

[View](/hu/documents/all-authorised-presentations/zynquista-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (623.33 KB - PDF)

**First published:**

16/05/2019

**Last updated:**

16/08/2022

[View](/mt/documents/all-authorised-presentations/zynquista-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (663.01 KB - PDF)

**First published:**

16/05/2019

**Last updated:**

16/08/2022

[View](/nl/documents/all-authorised-presentations/zynquista-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (599.37 KB - PDF)

**First published:**

16/05/2019

**Last updated:**

16/08/2022

[View](/no/documents/all-authorised-presentations/zynquista-epar-all-authorised-presentations_no.pdf)

polski (PL) (658.22 KB - PDF)

**First published:**

16/05/2019

**Last updated:**

16/08/2022

[View](/pl/documents/all-authorised-presentations/zynquista-epar-all-authorised-presentations_pl.pdf)

português (PT) (587.22 KB - PDF)

**First published:**

16/05/2019

**Last updated:**

16/08/2022

[View](/pt/documents/all-authorised-presentations/zynquista-epar-all-authorised-presentations_pt.pdf)

română (RO) (609.94 KB - PDF)

**First published:**

16/05/2019

**Last updated:**

16/08/2022

[View](/ro/documents/all-authorised-presentations/zynquista-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (653.56 KB - PDF)

**First published:**

16/05/2019

**Last updated:**

16/08/2022

[View](/sk/documents/all-authorised-presentations/zynquista-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (647.39 KB - PDF)

**First published:**

16/05/2019

**Last updated:**

16/08/2022

[View](/sl/documents/all-authorised-presentations/zynquista-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (667.97 KB - PDF)

**First published:**

16/05/2019

**Last updated:**

16/08/2022

[View](/fi/documents/all-authorised-presentations/zynquista-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (595.78 KB - PDF)

**First published:**

16/05/2019

**Last updated:**

16/08/2022

[View](/sv/documents/all-authorised-presentations/zynquista-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Zynquista Active substance sotagliflozin International non-proprietary name (INN) or common name sotagliflozin Therapeutic area (MeSH) Diabetes Mellitus, Type 1 Anatomical therapeutic chemical (ATC) code A10

### Pharmacotherapeutic group

Drugs used in diabetes

### Therapeutic indication

Zynquista is indicated as an adjunct to insulin therapy to improve glycaemic control in adults with type 1 diabetes mellitus with a Body Mass Index (BMI) ? 27 kg/m 2 , who have failed to achieve adequate glycaemic control despite optimal insulin therapy.

## Authorisation details

EMA product number EMEA/H/C/004889 Marketing authorisation holder

Guidehouse Germany GmbH

Geschäftsanschrift

Opinion adopted 27/02/2019 Marketing authorisation issued 26/04/2019 Withdrawal of marketing authorisation 22/03/2022 Revision 3

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Zynquista : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (677.27 KB - PDF)

**First published:** 04/02/2020

**Last updated:** 16/08/2022

[View](/en/documents/procedural-steps-after/zynquista-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Zynquista : EPAR - Public assessment report

Adopted

Reference Number: EMA/178275/2019

English (EN) (5.36 MB - PDF)

**First published:** 16/05/2019

**Last updated:** 16/08/2022

[View](/en/documents/assessment-report/zynquista-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Zynquista

Adopted

Reference Number: EMA/CHMP/138211/2019

English (EN) (655.25 KB - PDF)

**First published:** 01/03/2019

**Last updated:** 16/08/2022

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-zynquista_en.pdf)

#### News on Zynquista

[New add-on treatment to insulin for treatment of certain patients with type 1 diabetes](/en/news/new-add-treatment-insulin-treatment-certain-patients-type-1-diabetes) 01/03/2019

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25-28 February 2019](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-25-28-february-2019) 01/03/2019

#### More information on Zynquista

- [EMEA-001517-PIP02-14-M03 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001517-pip02-14-m03)

**This page was last updated on** 16/08/2022

## Share this page

[Back to top](#main-content)